Organ-selective chemoresistance in metastasis from human breast cancer cells: Inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus

Carcinogenesis

Volumn 25, Issue 12, 2004, Pages 2293-2301

  Gu, Bin ^a   Espanña, Laura ^a   Méndez, Olga ^a   Torregrosa, Angels ^b   Sierra, Angels ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; GENE PRODUCT; GENOMIC DNA; LUCIFERASE; NEOMYCIN; PACLITAXEL; PROTEIN BCL XL; TUMOR MARKER; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; DNA FINGERPRINTING; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; METASTASIS POTENTIAL; MICROENVIRONMENT; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; SOMATIC CELL GENETICS; TUMOR CELL; VISCERAL METASTASIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; BONE NEOPLASMS; BREAST NEOPLASMS; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DISEASE PROGRESSION; DNA FINGERPRINTING; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUCIFERASES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TRANSFECTION; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 10344250398     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh272     Document Type: Article

References (53)

1. Borg,A., Ferno,M. and Peterson,C. (2003) Predicting the future of breast cancer. Nature Med., 9, 16-18.
2. Strasser,A. (1999) Dr. Josef Steiner Cancer Research Prize Lecture: the role of physiological cell death in neoplastic transformation and in anti-cancer therapy. Int. J. Cancer, 81 505-511.
3. Nikiforov,M.A., Kwek,S.S., Mehta,R., Artwohl,J.E., Lowe,S.W., Gupta,T.D., Deichman,G.I. and Gudkov,A.V. (1997) Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. Oncogene, 15, 3007-3012.
4. Cameron,M.D., Schmidt,E.E., Kerkvliet,N., Nadkami,K.V., Morris,V.L., Groom,A.C., Chambers,A.F. and MacDonald,I.C. (2000) Temporal progression of metastasis in lung: cell survival, dormancy and location dependence of metastatic inefficiency. Cancer Res., 60, 2541-2546.
5. Wong,C.W., Lee,A., Shientag,L., Yu,J., Dong,Y., Kao,G., Al-Mehdi,A.B., Bernhard,E.J. and Muschel,R.J. (2001) Apoptosis: an early event in metastatic inefficiency. Cancer Res., 61, 333-338.
6. Zhu,Z., Sanchez-Sweatman,O., Huang,X., Wiltrout,R., Khokha,R., Zhao,Q. and Gorelik,E. (2001) Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res., 61, 1707-1716.
7. Minn,A.J., Swain,R.E., Ma,A. and Thompson,C.B. (1998) Recent progress on the regulation of apoptosis by Bcl-2 family members. Adv. Immunol., 70, 245-279.
8. Huang,D.C. and Strasser,A. (2000) BH3-Only proteins - essential initiators of apoptotic cell death. Cell, 103, 839-842.
9. Kroemer,G. (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med., 3, 614-620.
10. Fadeel,B., Zhivotovsky,B. and Orrenius,S. (1999) All along the watch-tower: on the regulation of apoptosis regulators. FASEB J. 13, 1647-1657.
11. Gross,A., McDonnell,J.M. and Korsmeyer,S.J. (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev., 13 1899-1911.
12. Poruchynsky,M.S., Wang,E.E., Rudin,C.M., Blagosklonny,M.V. and Fojo,T. (1998) Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res., 58, 3331-3338.
13. Decaudin,D., Geley,S., Hirsch,T., Castedo,M., Marchetti,P., Macho,A., Kofler,R. and Kroemer,G. (1997) Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res., 57, 62-67.
14. Haldar,S., Basu,A. and Croce,C.M. (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res., 57, 229-233.
15. Fang,G., Chang,B.S., Kim,C.N., Perkins,C., Thompson,C.B. and Bhalla,K.N. (1998) 'Loop' domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res., 58, 3202-3208.
16. Fernandez,Y., Gu,B., Martinez,A., Torregrosa,A. and Sierra,A. (2002) Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int. J. Cancer, 101 317-326.
17. Real,P.J., Sierra,A., De Juan,A., Segovia,J.C., Lopez-Vega,J.M. and Fernandez-Luna,J.L. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene, 21, 7611-7618.
18. Rubio,N., Espana,L., Fernandez,Y., Blanco,J. and Sierra,A. (2001) Metastatic behavior of human breast carcinomas overexpressing the Bcl-x (L) gene: a role in dormancy and organospecificity. Lab. Invest. 81, 725-734.
19. Zhang,R.D., Fidler,I.J. and Price,J.E. (1991) Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metast., 11 204-215.
20. Jäättelä,M., Benedict,M., Tewari,M. and al',J.A.S.e. Bcl-x and Bcl-2 inhibit TNT and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene.
21. Liu,R., Page,C., Beidler,D.R., Wicha,M.S. and Nunez,G. (1999) Overexpression of Bcl-x (L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am. J. Pathol., 155, 1861-1867.
22. Song,S., Wientjes,M.G., Gan,Y. and Au,J.L. (2000) Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl Acad. Sci. USA, 97, 8658-8663.
23. Arribas,R., Capella,G., Tortola,S., Masramon,L., Grizzle,W.E., Perucho,M. and Peinado,M.A. (1997) Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications. J. Clin. Oncol., 15, 3230-3240.
24. Shoemaker,R.H. (2000) Genetic and epigenetic factors in anticancer drug resistance. J. Natl Cancer Inst., 92, 4-5.
25. Taylor,S.T., Hickman,J.A. and Dive,C. (2000) Epigenetic determinants of resistance to etoposide regulation of Bcl-X (L) and Bax by tumor microenvironmental factors. J. Natl Cancer Inst., 92 18-23.
26. Liotta,L.A. and Kohn,E.C. (2001) The microenvironment of the tumour-host interface. Nature, 411, 375-379.
27. Ladeda,V., Adam,A.P., Puricelli,L. and Bal de Kier Joffe,E. (2001) Apoptotic cell death in mammary adenocarcinoma cells is prevented by soluble factors present in the target organ of metastasis. Breast Cancer Res. Treat., 69, 39-51.
28. Evan,G.I. and Vousden,K.H. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-348.
29. Wells,A. (2000) Tumor invasion: role of growth factor-induced cell motility. Adv. Cancer Res., 78, 31-101.
30. Ellis,P.A., Smith,I.E., Detre,S., Burton,S.A., Salter,J., A'Hern,R., Walsh,G., Johnston,S.R. and Dowsett,M. (1998) Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res. Treat., 48, 107-116.
31. Jordan,M.A. and Wilson,L. (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol., 10, 123-130.
32. Nabholtz,J.M., Tonkin,K., Smylie,M., Au,H.J., Lindsay,M.A. and Mackey,J. (2000) Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert. Opin. Pharmacother., 1, 187-206.
33. Burstein,H.J., Manola,J., Younger,J. et al. (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol., 18, 1212-1219.
34. 2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J. Clin. Oncol., 19, 336-342.
35. Lippman,M.E. and Hayes,D.F. (2001) Adjuvant therapy for all patients with breast cancer? J. Natl Cancer Inst., 93, 80-82.
36. Conze,D., Weiss,L., Regen,P.S., Bhushan,A., Weaver,D., Johnson,P. and Rincon,M. (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res., 61, 8851-8858.
37. Bissery,M.C., Nohynek,G., Sanderink,G.J. and Lavelle,F. (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs, 6 339-355, 363-368.
38. Boven,E., Venema-Gaberscek,E., Erkelens,C.A., Bissery,M.C. and Pinedo,H.M. (1993) Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. Ann. Oncol., 4, 321-324.
39. Sparreboom,A., van Tellingen,O., Nooijen,W.J. and Beijnen,J.H. (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs, 9, 1-17.
40. Bissery,M.C., Guenard,D., Gueritte-Voegelein,F. and Lavelle,F. (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res., 51, 4845-4852.
41. Fernandez,Y., Espana,L., Manas,S., Fabra,A. and Sierra,A. (2000) Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Cell Death Differ., 7, 350-359.
42. Fidler,I.J. (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Rev. Cancer, 3, 453-458.
43. Bernards,R. and Weinberg,R.A. (2002) A progression puzzle. Nature, 418, 823.
44. Zhang,L., Yu,J., Park,B.H., Kinzler,K.W. and Vogelstein,B. (2000) Role of BAX in the apoptotic response to anticancer agents. Science, 290, 989-992.
45. Hellman,S. (1997) Darwin's clinical relevance. Cancer, 79, 2275-2281.
46. Debatin,K.M., Poncet,D. and Kroemer,G. (2002) Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene, 21, 8786-8803.
47. Simoes-Wust,A.P., Schurpf,T., Hall,J., Stahel,R.A. and Zangemeister-Wittke,U. (2002) Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat., 76, 157-166.
48. Stenner-Liewen (2003) Cancer Res.
49. Fidler,I.J. (1999) Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother. Pharmacol., 43, S3-10.
50. Ramaswamy,S., Ross,K.N., Lander,E.S. and Golub,T.R. (2003) A molecular signature of metastasis in primary solid tumors. Nature Genet., 33, 49-54.
51. van't Veer,L.J., Dai,H., van de Vijver,M.J., He,Y.D., Hart,A.A., Bernards,R. and Friend,S.H. (2002) Expression profiling predicts outcome in breast cancer. Breast Cancer Res., 5, 57-58.
52. van de Vijver,M.J., He,Y.D., van't Veer,L.J. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 347, 1999-2009.
53. van't Veer,L.J., Dai,H., van de Vijver,M.J. et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536.